GEVA was up on big volume today. Are they an acquisition target? Who would buy - Alexion? Who else is a player in the ultra-rare space that would benefit from buying GEVA?
The high volume was because GEVA was just added to the NASDAQ biotech index, so any biotech index fund or manager that tracks the index had to buy GEVA. That said it's likely that Baker Brothers have an exit in mind.